Kite Pharma, Inc. (NASDAQ:KITE) EVP Helen Susan Kim sold 26,649 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $109.28, for a total value of $2,912,202.72. Following the completion of the sale, the executive vice president now directly owns 28,763 shares in the company, valued at approximately $3,143,220.64. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Helen Susan Kim also recently made the following trade(s):
- On Thursday, August 10th, Helen Susan Kim sold 6,251 shares of Kite Pharma stock. The stock was sold at an average price of $120.09, for a total value of $750,682.59.
- On Tuesday, August 8th, Helen Susan Kim sold 79,949 shares of Kite Pharma stock. The shares were sold at an average price of $119.56, for a total value of $9,558,702.44.
Shares of Kite Pharma, Inc. (KITE) traded up 3.29% during midday trading on Friday, hitting $130.18. The stock had a trading volume of 1,058,415 shares. The company’s 50-day moving average price is $111.51 and its 200-day moving average price is $84.63. Kite Pharma, Inc. has a 12-month low of $39.82 and a 12-month high of $130.64. The firm’s market cap is $7.44 billion.
Kite Pharma (NASDAQ:KITE) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.03. The company had revenue of $10.10 million for the quarter, compared to analyst estimates of $9.59 million. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. Kite Pharma’s revenue for the quarter was up 110.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.91) EPS. Equities research analysts forecast that Kite Pharma, Inc. will post ($8.19) EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KITE. BlackRock Inc. raised its position in shares of Kite Pharma by 106,272.1% in the first quarter. BlackRock Inc. now owns 3,621,971 shares of the biopharmaceutical company’s stock worth $284,287,000 after buying an additional 3,618,566 shares during the period. Point72 Asset Management L.P. raised its position in shares of Kite Pharma by 235.0% in the first quarter. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company’s stock worth $64,354,000 after buying an additional 575,178 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kite Pharma by 16.1% in the first quarter. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company’s stock worth $287,395,000 after buying an additional 507,289 shares during the last quarter. Columbia Wanger Asset Management LLC acquired a new position in shares of Kite Pharma during the first quarter worth about $35,452,000. Finally, Norges Bank acquired a new position in shares of Kite Pharma during the fourth quarter worth about $16,848,000. Institutional investors own 83.94% of the company’s stock.
Several research analysts have weighed in on the company. UBS AG downgraded Kite Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, May 8th. Canaccord Genuity set a $120.00 price target on Kite Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $135.00 price target (up from $121.00) on shares of Kite Pharma in a report on Wednesday, August 9th. Stifel Nicolaus reissued a “hold” rating and issued a $74.00 price target on shares of Kite Pharma in a report on Thursday, August 10th. Finally, Vetr cut Kite Pharma from a “buy” rating to a “hold” rating and set a $116.82 price target for the company. in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $88.93.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with our FREE daily email newsletter.